NASDAQ · EXAS
Healthcare · Medical - Diagnostics & Research
$104.91
Up+$0.00 (+0.00%)
Updated Sep 11, 2026, 1:40 AM
SID Score
6.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
EXAS does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning EXAS.
EXAS research
Company profile and research snapshot.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 20, 2026 | Mizuho | Neutral | — |
| Jan 5, 2026 | Evercore ISI Group | In-Line | — |
| Nov 25, 2025 | Canaccord Genuity | Hold | — |
| Nov 24, 2025 | Benchmark | Hold | — |
| Nov 24, 2025 | Jefferies | Hold | — |
No generated briefing is available yet.
Benzinga · Mar 20, 2026
As previously communicated, this transaction is expected to add approximately $3 billion of incremental sales in 2026, accelerate Abbott's 2026 sales growth by approximately 0.5% and dilute 2026 adjusted earnings per
ChartMill · Mar 4, 2026
EXACT SCIENCES (EXAS) exemplifies a high-growth momentum stock, meeting strict technical trend rules and showing accelerating earnings and sales fundamentals.
Benzinga · Feb 23, 2026
https://www.bloomberg.com/news/articles/2026-02-23/abbott-laboratories-kicks-off-bond-sale-for-exact-sciences-deal
Benzinga · Feb 20, 2026
At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Sciences common stock as of the January 9, 2026 record date
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EXAS.
